pharmaphorum

DECEMBER 9, 2021

Heather Barnes, external innovation lead EMEA at Johnson and Johnson Consumer Health, is a scientist who is truly passionate about consumer health. With her background in biochemistry and eye for identifying innovation trends, the future is bright at Johnson & Johnson Innovation. Self care, skin health and technology innovation.

Allergies 105

Allergies Life Science Development Scientist 105

Scienmag

JUNE 14, 2021

June 4, 2021 A team of scientists has shown that the healing of skin blisters is driven by hair follicle stem cells, which delay their own development in the process. Credit: Yu Fujimura, et al. EMBO Reports. The healing process of the tissues in the human body is particularly well-studied in skin, especially as skin […].

Scientist 58

Scientist Development Dermatology Medicine 58

Scienmag

JUNE 17, 2021

Scientists […]. Engineers impressed by the functional great diversity of hairs on spider legs Credit: B Poerschke, SN Gorb and F Schaber Just how do spiders walk straight up — and even upside-down across — so many different types of surfaces?

Engineer 52

Engineer Scientist Dermatology 52

Scienmag

OCTOBER 6, 2020

Credit: Photo by Tommy Martino MISSOULA – University of Montana scientist Monica Serban is on a research roll. In recent months the UM associate professor and her team have earned three awards totaling $3.9 million in funding to study preventing hearing loss among U.S. For […].

Research 52

Research Scientist Production Dermatology 52

The Pharma Data

MAY 1, 2023

Associate Clinical Professor of Dermatology at the University of California San Francisco (UCSF), Director of Medical Dermatology Consultative Services and Patch Testing for the Palo Alto Foundation Medical Group and lead author on the face and hand analysis.

Dermatology 40

Dermatology Medicine Clinical Trials Clinical Trials 40

The Pharma Data

NOVEMBER 29, 2021

Primary results were presented at the American Academy of Dermatology Virtual Meeting Experience in April 2021, and fresh analyses were presented at the European Academy of Dermatology and Venereology 30th Anniversary Congress in September 2021.

Medicine 52

Medicine Drugs Dermatology Trials 52

Scienmag

MARCH 5, 2021

These frequently occurring skin diseases are mostly attributed by biomedical scientists to a disturbed immune system, although the noticeable thickening and flaking of the epidermis, which is the outermost layer of […].

Genetics 40

Genetics Scientist Dermatology Medicine 40

Olympian Clinical Research

NOVEMBER 16, 2022

According to the American Academy of Dermatology , scientists believe that when a hair follicle becomes clogged with keratin, bacteria breed within it. With offices in Tampa, Clearwater and Saint Petersburg, FL, we are dedicated to advancing the field of dermatology through clinical research.

Clinical Research 52

Clinical Research Bacteria Dermatology Immune Response 52

XTalks

JUNE 10, 2024

When psoriasis gets really bad, it’s really hard to get up again,” shared popstar Cindy Lauper in an interview with the American Academy of Dermatology Association. It is a sentiment that heavily resonates within the psoriasis community. More About Psoriasis About 7.55

Immune Response 52

Immune Response Dermatology Clinical Trials Clinical Trials 52

pharmaphorum

JULY 8, 2022

Thread is helping customers create and utilise digital endpoints in therapeutic areas like dermatology, respiratory, and CNS applications where the voice data capture is becoming important. It’s super innovative and requires our industry to build an endpoint into a process. About the author.

Clinical Trials 100

Clinical Trials Clinical Trials Trials Regulation 100

The Pharma Data

OCTOBER 9, 2021

Bristol Myers Squibb scientists designed deucravacitinib to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-23, IL-12 and Type 1 interferon (IFN), key cytokines involved in the pathogenesis of multiple immune-mediated diseases.

Trials 52

Trials Immune Response Dermatology Clinical Trials 52

The Pharma Data

DECEMBER 15, 2020

Klisyri is a home-grown product discovered and characterized by Athenex scientists and developed from pre-IND to NDA by the Athenex team. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. The FDA approval of Klisyri is a significant milestone for Athenex.

FDA Approval 52

FDA Approval Development Production Drugs 52

The Pharma Data

JUNE 7, 2022

Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe. Lilly has exclusive rights for development and commercialization of lebrikizumab in the United States and the rest of the world outside Europe. About Lebrikizumab.

Trials 40

Trials Clinical Trials Clinical Trials Medicine 40

Scienmag

NOVEMBER 18, 2020

“Framing race […].

Gene 52

Gene Research Dermatology Scientist 52

The Pharma Data

JUNE 19, 2022

A new study led by Penn State College of Medicine scientists finds that another type of immune cell – natural killer cells – can be harnessed to pick up the slack when T cells no longer work and may also reinvigorate T cells to attack melanoma tumors.

Drugs 52

Drugs Protein Immune Response Scientist 52

pharmaphorum

MAY 14, 2021

” Former FDA chief scientist and former acting FDA commissioner Stephen Ostroff, told Reuters that the company’s inconsistent statements are a “red flag”. But one of the study’s authors, Brown University dermatology professor Carlos Wambler, dismissed critics and called findings “very encouraging”.

Drug Trials 52

Drug Trials Trials Drugs Dermatology 52

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 52

Production Dermatology Development Containment 52

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 40

Production Dermatology Development Containment 40

The Pharma Data

AUGUST 11, 2020

Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Immune-Mediated Skin and Dermatologic Adverse Reactions. Immune-Mediated Encephalitis.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Immune-Mediated Skin and Dermatologic Adverse Reactions. Immune-Mediated Encephalitis.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

World of DTC Marketing

AUGUST 1, 2021

The CEOs of companies are the main messengers on boosters as opposed to scientists. As if all that wasn’t enough, Spherix Global Insights reveal ed a survey of 252 specialists in dermatology, gastroenterology, nephrology, neurology, and rheumatology, fielded on July 25, revealed confidence in the FDA is swiftly dwindling.

Vaccination 290

Vaccination Vaccine Dermatology Marketing 290

The Pharma Data

FEBRUARY 22, 2021

Discovered and developed by AbbVie scientists, RINVOQ is an oral, once daily, selective and reversible JAK inhibitor studied in several immune-mediated inflammatory diseases. European Academy of Dermatology and Venerology Congress. About Upadacitinib (RINVOQ). 3 In August 2019 , RINVOQ received U.S. Pipeline – Our Science | AbbVie.

Medicine 52

Medicine Development Drugs Trials 52

The Pharma Data

AUGUST 5, 2021

About Upadacitinib (RINVOQ ® ) 4 Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Additional endpoints at week 24 included EASI 75, EASI 90, EASI 100 and improvement from baseline Worst Pruritus NRS (weekly average).

Medicine 52

Medicine Dermatology Bacteria Vaccination 52

XTalks

AUGUST 2, 2023

It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy. It was founded in 2008 by Dr. Ugur Sahin and Dr. Özlem Türeci, a husband-and-wife team of scientists and physicians. The company’s areas of focus include urology, immunology, cardiology, dermatology and infectious diseases.

Sales 98

Sales Manufacturing FDA Approval Life Science 98